(+)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis

Eur J Pharmacol. 1984 Oct 30;106(1):185-9. doi: 10.1016/0014-2999(84)90694-0.


Both enantiomers of the dopamine analogue 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP; 0.5-32 mg/kg s.c.) dose dependently reduced the increase in striatal dopamine (DA) synthesis rate produced by gamma-butyrolactone (GBL). Whereas (+)-3-PPP completely prevented the action of GBL, (-)-3-PPP was only partially effective. In addition, (-)-3-PPP partially antagonised the inhibitory action of apomorphine on the GBL-induced increase in DA synthesis rate. These findings suggest that (+)- and (-)-3-PPP act as full and partial agonists respectively, at striatal DA autoreceptors controlling DA synthesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Butyrolactone / pharmacology
  • Animals
  • Apomorphine / pharmacology
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism*
  • Dopamine / biosynthesis*
  • Isomerism
  • Male
  • Piperidines / pharmacology*
  • Rats
  • Rats, Inbred Strains
  • Receptors, Dopamine / drug effects*
  • Receptors, Neurotransmitter / drug effects


  • Piperidines
  • Receptors, Dopamine
  • Receptors, Neurotransmitter
  • preclamol
  • Apomorphine
  • 4-Butyrolactone
  • Dopamine